Regeneron Pharmaceuticals Inc. buy Saftman
Summary
This prediction ended on 08.07.22 with a price of €592.90. The BUY prediction by Saftman finished with a performance of 21.00%. Saftman has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Regeneron Pharmaceuticals Inc. | -1.902% | -1.902% | 17.050% |
iShares Core DAX® | 2.594% | -1.158% | 14.782% |
iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% |
iShares Nikkei 225® | 0.687% | -8.354% | 18.454% |
iShares S&P 500 | 2.209% | -0.942% | 31.361% |
Comments by Saftman for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.